Severe COVID-19 Pneumonia and Critical Congenital Heart Disease in a Newborn
PDF
Cite
Share
Request
Case report
VOLUME: 33 ISSUE: 1
P: 142 - 145
2023

Severe COVID-19 Pneumonia and Critical Congenital Heart Disease in a Newborn

Anatol J Gen Med Res 2023;33(1):142-145
1. Acıbadem University Faculty of Medicine, Department of Pediatric Cardiology, İstanbul, Turkey
2. Acıbadem University Faculty of Medicine, Department of Pediatric Cardiovascular Surgery, İstanbul, Turkey
3. Acıbadem University Faculty of Medicine, Department of Neonathology, İstanbul, Turkey
4. Acıbadem University Faculty of Medicine, Department of Pediatric Infectious Disease, İstanbul, Turkey
No information available.
No information available
Received Date: 2021-07-01T14:28:25
Accepted Date: 2023-04-10T14:19:53
PDF
Cite
Share
Request

Abstract

The new coronavirus infection, which has resulted in a pandemic, may lead to pneumonia, severe respiratory insufficiency, multi-organ failure, and death in adults and elderly as well as people with chronic diseases. As the number of people affected by this globall pandemic, patients in all age groups are being identified with more reported neonatal and pediatric patients. It has been reported that neonates and infants with a congenital cardiac disease constitute the most commonly affected group. Favipiravir may be administered in case of coronavirus disease-2019 (COVID-19) pneumonia that starts in the neonatal period. Here, we report a newborn with an interrupted aortic arch and severe COVID-19 pneumonia. The patient, who had severe COVID pneumonia, was successfully operated after being treated.

Keywords:
COVID-19, pneumonia, newborn, interrupted aortic arch, favipiravir